TELO · Telomir Pharmaceuticals, Inc.
AI read · Good for TELO
The AI's read
This gives Telomir a partner with experience running cancer studies, including early-stage trials. The signed work plan sets up a start targeted for Q1 2027. That is a real step toward testing Telomir-Zn in patients. The study has not started, and no results are reported. Patient recruitment, safety, and funding could still delay or stop it.